A Safety Pilot Study of Px-104 in non alcoholic fatty liver disease (NAFLD) patients
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2016
At a glance
- Drugs PX 104 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions
- Sponsors Phenex Pharmaceuticals
- 29 Sep 2016 Biomarkers information updated
- 02 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 26 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016 as per ClinicalTrials.gov record.